3 things to keep in mind about trans (men’s) inclusion in HIV prevention research

By Ayden Scheim In response to mounting evidence of the prevention benefits of pre-exposure prophylaxis (PrEP) use by HIV-negative gay and bisexual men, a discussion recently emerged on social media about the perceived exclusion of trans men1 who have sex with men from PrEP research studies. In fact, trans men participate in many HIV prevention research studies, whether or not they are identified as trans when results are reported. Some do not identify as trans, but rather as men of trans experience or transitioned men, and are happy to check the “male” box without qualification. Other studies have explicitly included...

Read more

Breaking the ice in Northern Manitoba

By Melissa Egan It’s cold in Thompson, Manitoba. The snow squeaks and the roads are nearly pure ice; everyone drives a truck up here. I’ve arrived here to do a three-day training alongside Gina McKay from Sexuality Education Resource Centre and Carrie Pockett from Play it Safer Network. With some resources from Keewatin Tribal Council’s Adele Sweeny, we’ll be spending time with 25 people from 16 First Nations communities in the area.

Read more

There is a drug to prevent HIV. Why isn’t it approved in Canada?

By Bob Leahy Recent developments in prevention are pointing to worrying gaps in the community-based approach to HIV prevention in Canada. Perhaps we have been used to having only a single prevention technology on our books for so long – think condoms – that our ducks are not always in a row when new ones like PrEP come along. Thus potholes in our response become apparent – and none leap in to fix them. After a series of somewhat inconclusive PrEP trials, whose results were marred by adherence issues, the results of more stringent trials like the PROUD and IPERGAY...

Read more

Cured of Hep C, but still living with it

By Hermione Jefferis What happens when much of your life is built around a particular position or identity, and then that identity changes? In 1993, while in the hospital having my daughter, I was diagnosed with hepatitis C. Three years ago, I did the ribavirin and pegylated interferon treatment and cleared the virus. It’s very cool to be living virus-free after 25+ years of being positive, but it is also kind of weird.

Read more

Déjà vu: Canada’s drug reviewers again mired in bureaucracy

By Adam Cook The development of treatment for the cure of hepatitis C (HCV) is moving at a dizzying pace. Indeed, the entire HCV story is one of an unusually fast trajectory, not only the speed of treatment development, but also the spread of the virus. While early cures were injection-based, difficult to tolerate, and boasting a mere 50% success rate after a year of treatment, there now exist cures that involve one pill, once a day, for a regimen that often doesn’t exceed twelve weeks. There are clinical trials being conducted presently to evaluate the efficacy of new treatments...

Read more